Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort

Karine Lacombe; Hélène Fontaine; Catherine Dhiver; Sophie Métivier; Eric Rosenthal; Teresa Antonini; Marc Antoine Valantin; Patrick Miailhes; Stanislas Harent; Dominique Batisse; Georges-Philippe Pageaux; Julie Chas; Hugues Aumaitre; Stéphanie Domínguez; Thierry Allègre; Alain Lafeuillade; Eric Billaud; Pierre de Truchis; Philippe Perre; Vincent Leroy; Victor de Ledinghen; Philippe Sogni; Francois Dabis; Yue Zhao; Anne Filipovics; Larysa Fedchuk; Raoudha Akremi; Yacia Bennai; Dominique Salmon Ceron

doi:10.1097/QAI.0000000000001342

Retour

Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort

Article de revue

Avec comité de lecture

Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort

Karine Lacombe, Hélène Fontaine, Catherine Dhiver, Sophie Métivier, Eric Rosenthal, Teresa Antonini, Marc Antoine Valantin, Patrick Miailhes, Stanislas Harent, Dominique Batisse, …

Journal of acquired immune deficiency syndromes (1999), Vol.75(1), pp.97-107

01/05/2017

DOI: https://doi.org/10.1097/QAI.0000000000001342

PMID: 28272163

Résumé

Human health and pathology

Immunology

Infectious diseases

Life Sciences

Efficacious, well-tolerated, direct antiviral agents have drastically changed the prognosis of hepatitis C virus (HCV) disease, but real-world data for oral treatments are limited in key populations such as HIV/HCV coinfection with advanced liver disease. Daclatasvir (DCV) efficacy and safety was assessed in the French "Autorisation Temporaire d'Utilisation" (ATU) program, providing DCV ahead of market authorization to patients with advanced HCV disease without other treatment options.

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort
Créateurs - sans rôle: Karine Lacombe - CHU Saint-Antoine [AP-HP]
Hélène Fontaine - Département d'hépatologie [CHU Cochin]
Catherine Dhiver - Hôpital de la Conception
Sophie Métivier - Pôle Maladies de l'appareil digestif [CHU Toulouse]
Eric Rosenthal - Centre Hospitalier Universitaire de Nice
Teresa Antonini - Centre hépato-biliaire
Marc Antoine Valantin - Charmo University
Patrick Miailhes - Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL]
Stanislas Harent - Services de Maladies Infectieuses et Tropicales [CHU Bichat]
Dominique Batisse - Service d'immunologie [HEGP, Paris]
Georges-Philippe Pageaux - Centre Hospitalier Régional Universitaire [Montpellier]
Julie Chas - CHU Tenon [AP-HP]
Hugues Aumaitre - Centre Hospitalier Saint Jean de Perpignan
Stéphanie Domínguez - Service d'immunologie clinique [Créteil]
Thierry Allègre - Centre Hospitalier du Pays d'Aix
Alain Lafeuillade
Eric Billaud - Service de maladies infectieuses et tropicales [Nantes]
Pierre de Truchis - Service des Maladies Infectieuses et Tropicales [CHU Raymond Poincaré]
Philippe Perre - Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon
Vincent Leroy - Département d'hépato-gastroentérologie
Victor de Ledinghen - Hôpital Haut-Lévêque [CHU Bordeaux]
Philippe Sogni - Service d'hépatologie médicale [CHU Cochin]
Francois Dabis - Bordeaux Population Health
Yue Zhao
Anne Filipovics
Larysa Fedchuk
Raoudha Akremi
Yacia Bennai
Dominique Salmon Ceron - Département d'hépatologie [CHU Cochin]
Détails de publication: Journal of acquired immune deficiency syndromes (1999), Vol.75(1), pp.97-107
Éditeur: Lippincott, Williams & Wilkins
Nombre de pages: 11
Identifiants: 99139791309311
Unité académique: Institut de Génétique Moléculaire de Montpellier - IGMM
Langue: English
Type de ressource: Journal article